Robert Z. Tashjian

Healing after rotator cuff repair (RCR) can be challenging, especially in cases of large and massive tears, revision repairs, and tendons with poor tissue quality.^1-3 Poor tissue quality is associated with increased risk for recurrent tears, independent of age and tear size.³ Various techniques have been used to improve tendon fixation strength in these difficult situations, including augmented suture configurations (eg, massive cuff stitches, rip-stop stitches) and tissue grafts (eg, acellular dermal matrix).^4-9 Clinical studies have found improved healing rates for larger tears and revision repairs using acellular dermal matrix grafts.^6,10 Synthetic patches are another option for RCR augmentation, but limited clinical data and biomechanical evidence support use of synthetic grafts as an augment for RCRs.^11-13

Polyhydroxyalkanoates (PHAs) are a class of biodegradable polymers that have been used as orthopedic devices, tissue scaffolds, patches, and other applications with increasing frequency over the past decade.¹⁴ In the laboratory, these implanted materials have been shown to support cell migration and growth.¹⁵ The PHA family of polymers typically degrades by hydrolytic and bacterial depolymerase mechanisms over 52-plus weeks in vivo.¹⁴PHA grafts have been studied in the setting of RCR. An expanded polytetrafluoroethylene scaffold was shown to improve repair mechanics when used as a bursal side graft in an in vitro ovine model.¹¹ The graft increased tendon footprint contact pressure and failure loads by almost 180 N. In clinical studies, poly-L-lactic acid augmentations have been used to reinforce massive RCRs. Lenart and colleagues¹⁶ found that 38% of 16 patients with such tears had an intact rotator cuff at 1.2-year follow-up, and improvement in clinical scores. Proctor¹³ reported on use of a poly-L-lactic acid retrograde patch for reinforcement of massive tears with both single- and double-row repairs in 18 patients. The cohort had more favorable rates of intact cuffs at 12 months (83%) and 42 months (78%), and ASES (American Shoulder and Elbow Surgeons) scores improved from 25 before surgery to 82 at latest follow-up after surgery.

RCR augmentation traditionally has been performed with an open or mini-open technique.⁶ Recently, several authors have reported on arthroscopic techniques for augmentation with either acellular dermal matrix or synthetic grafts.^13,17,18 Most techniques have involved “bridging” with a graft or patch used to stress-shield a single-row repair.^8,9,13 This bridging typically involves placing several sutures medial to where the anchor repair stitches pass through the tendon. An alternative is to pass the repair stitches through both the tendon and the graft.^17-19 The overall volume of tissue incorporated into the repair stitches (rotator cuff plus graft) is increased with the augmented technique relative to the bridging technique. Both can be technically challenging, but the augmented technique may be easier to perform arthroscopically.^9,19 Regardless, these techniques are complicated and require a higher level of arthroscopic skills compared with those required in arthroscopic RCR without a graft. Simplifying arthroscopic graft augmentation likely will increase its utility because, even for skilled surgeons, adding a graft can increase operative time by 20 to 30 minutes. Simplification will also extend use of the technique to surgeons with less experience and proficiency with arthroscopic repair.

We developed a simple method for augmenting single-row RCR with a strip of bioresorbable soft-tissue scaffold. We also conducted a study to evaluate the initial biomechanical properties of single-row RCR in cadaveric shoulder specimens augmented with PHA mesh (BioFiber; Tornier) graft as compared with single-row RCR without augmentation. Both cyclic gap formation and ultimate failure loads and displacement were quantified. We hypothesized that the augmented RCRs would have decreased gap formation and increased ultimate failure loads compared with nonaugmented RCRs. This study was exempt from having to obtain Institutional Review Board approval.

Methods

Eight pairs of fresh-frozen cadaver humeri (6 male, 2 female; mean [SD] age, 61 [9] years) were dissected of all soft tissue (except rotator cuff) by Dr. Tashjian, a board-certified, fellowship-trained orthopedic surgeon. There were no qualitative differences in tendon condition between tendons within a pair. The supraspinatus muscle and tendon were separated from the other rotator cuff muscles. The infraspinatus, subscapularis, and teres minor were removed from the humerus. Last, the supraspinatus was resected at its insertion. Humeral pairs were then randomized into augmented and nonaugmented RCRs within each pair.

In the nonaugmented group, the supraspinatus was reattached to its insertion in a single-row RCR with 2 triple-loaded suture anchors (5.5-mm Insite FT Ti, No. 2 Force Fiber suture; Tornier) and 6 simple stitches (Figure 1A). Anchors were placed midway between the articular margin and the lateral edge of the greater tuberosity at about 45° to the bone surface.

Anchors were separated by 15 mm, with the anterior anchor 5 mm posterior to the biceps groove. Stitches were passed through the supraspinatus tendon, taking a 15-mm bite of tissue, with each stitch separated by 5 mm. Each suture was then tied with a Revo knot.

In the contralateral shoulders, augmented RCRs were performed. Specimens were prepared exactly as they were for the nonaugmented RCRs, including anchor placement and suture passage. Before knot tying, RCRs were augmented with 2 strips of 13-mm × 23-mm PHA mesh (BioFiber) (Figure 1B). One strip was used to augment the 3 sutures of each anchor, overlying the residual tendon, to reinforce the tendon–knot interface. After each suture was passed through the supraspinatus tendon from the intra-articular surface, the stitch was passed through the strip of PHA mesh. Stitches were separated by 5 mm in each mesh strip. All 6 sutures were then tied with a Revo knot between the free end of each suture leg and the leg that passed through the tendon and mesh.

Each humerus was transected at the midshaft and potted and mounted in an Instron 1331 load frame with Model 8800 controller (Instron). A cryoclamp was used to grasp the supraspinatus muscle belly above the musculotendinous junction (Figure 2).

The humerus was aligned in the mounting fixture such that loading was performed at a 135° angle with the humeral shaft (Figure 2).²⁰ The Instron, which was equipped with a 1-kN load cell (Dynacell Model 2527-130; Instron) to monitor applied force, measured applied displacement.

Three rows of 2-mm fiducial markers were affixed to the bone, tendon, and muscle belly with cyanoacrylate for tracking with a digital video system (DMAS Version 6.5; Spicatek) (Figure 3).21

Camera resolution was 1360 pixels × 1024 pixels, and DMAS accuracy for marker centroid tracking was rated at ± 0.005 mm. Construct gapping was defined as the difference in displacement between the markers at the tissue–suture interface and the markers on the bone. Tissue deformation was then defined as the displacement between the markers at the tissue–suture interface and the markers on the muscle belly. Mean gapping was defined from anterior to posterior across the construct using 3 sets of fiducial markers.

A 0.1-MPa pre-stress (applied force/tendon cross-sectional area) was applied to each construct to determine the starting position for the deformation profile. Each repair underwent 1000 cycles of uniaxial load-controlled displacement between 0.1 and 1.0 MPa of effective stress at 1 Hz. Effective stress was determined as the ratio of applied force to cross-sectional area of the tendon at harvest to normalize the applied loads between tendons of varying size. During cyclic testing, gapping of more than 5 mm was defined as construct failure.²² After cyclic loading, each construct was loaded to failure at 1.0 mm/s. Ultimate failure load was defined as the highest load achieved at the maximum displacement before rapid decline in load supported by the construct.

 

Statistical Analysis

Paired t tests were used to compare the matched pairs of constructs. For all tests, significance was set at P ≤ .05. Post hoc power was calculated for significant results using G*Power Version 3.1.6.²³ All data are presented as means (SDs).

Results

After 1000 cycles of displacement, mean (SD) gapping was 3.8 (0.9) mm for the nonaugmented repairs and 3.9 (1.1) mm for the PHA mesh–augmented repairs (P = .879) (Figure 4).

Mean (SD) tissue elongation above the construct was comparable (P = .276) between nonaugmented repairs, 0.5 (0.4) mm, and augmented repairs, 0.7 (0.4) mm. No specimens failed during cyclic load, as mean gapping was <4 mm²² in all constructs. Mean (SD) applied force was 11.8 (1.8) N at 0.1 MPa of effective stress and 117.8 (18.1) N at 1.0 MPa of effective stress. Applied force did not vary between constructs (P = .727).

For the nonaugmented repairs, mean (SD) failure displacement was 6.3 (1.7) mm, and mean (SD) ultimate failure load was 472.1 (120.3) N. For the PHA-augmented repairs, failure displacement was 5.5 (1.9) mm, and ultimate failure load was 571.2 (173.0) N. There was no difference in failure displacement (P = .393), but there was a difference in ultimate failure load (P = .042; power = 0.57). During failure testing, mean (SD) tissue deformation was higher (P = .012; power = 0.83) for the PHA-augmented repairs, 1.2 (0.7) mm, than for the nonaugmented repairs, 0.8 (0.5) mm. Failures, which were consistent within pairs, were caused by tissue failure, with sutures pulling through the tissue (4 pairs) or single anchor pullout before ultimate tissue failure (4 pairs). Of the 4 failures with anchor pullout, 3 had anterior anchor pullout, and 1 had posterior anchor pullout. In all specimens with anchor pullout, the second anchor remained stable, and ultimate failure occurred with tissue tearing at the suture interface. There were no significant differences in any metrics between specimens that failed with intact anchors and specimens with single anchor pullout (P ≥ .122). Therefore, both groups were pooled for the failure analysis.

Discussion

RCR augmentation with a synthetic graft is a viable option for improving fixation strength of supraspinatus repairs, as shown in otherwise healthy tendon in the present study. Our hypothesis that there would be decreased gap formation with graft augmentation was not supported, whereas the hypothesis of increased failure loads with graft augmentation was supported. These findings may also be applicable in cases of large tears, revisions, and tendons with poor tissue quality. Simplification of graft application techniques will allow quick and easy arthroscopic augmentation.

Studies of RCRs for large or massive tears have reported retear rates of 25% to 79%.^24-26 Latissimus dorsi tendon transfers also show promise in posterosuperior RCRs, with failure rates near 10%.^27,28 Although use of PHA patches in RCR augmentation is relatively new, short-term and midterm failure rates are in the range of 20% to 60% in the few small cohorts currently being studied.^13,16 It is possible that these rates may improve as indications, surgical experience, and techniques for use of PHA patches are further refined. Regardless, with PHA currently being used in practice, it is important to quantify the biomechanics of the augmentation as a baseline for its performance in reinforcing the tendon–suture interface.

We determined that the initial fixation strength of single-row repairs was higher with the addition of PHA synthetic grafts using a very simple technique. Single-row triple-loaded anchor repairs already provide high initial mechanical strength, and our results are similar to those of another study of this technique.²⁹ Despite the already high mechanical strength of a triple-loaded anchor repair, PHA mesh increased ultimate strength by about 100 N (~25%). Of note, tissue elongation during failure was higher (P = .012; power = 0.83) in the PHA-augmented group (1.2 mm) than in the nonaugmented group (0.8 mm). This was not surprising—failure loads were almost 100 N higher in the PHA-augmented group than in the nonaugmented group. Consequently, much higher forces were placed on the muscle belly, likely resulting in additional elongation of the intact tissue medial to the repair construct.

The ultimate failure loads in our study compare favorably with the biomechanical strength of augmented repairs reported by others.^8,9,18 Barber and colleagues¹⁸ evaluated an augmented single-row repair with 2 double-loaded suture anchors and an acellular dermal matrix graft. The ultimate failure load of the augmented repairs was 325 N. In contrast, Omae and colleagues⁸ tested a bridging single-row repair using 2 double-loaded suture anchors and an acellular dermal matrix graft. Ultimate failure load of the augmented repairs was 560 N, similar to our finding. Last, Shea and colleagues⁹ evaluated a bridging single-row repair using 2 double-loaded suture anchors and an acellular dermal matrix graft, with ultimate failure load of 429 N. The techniques in all 3 studies can be performed arthroscopically but are challenging and require multiple extra sutures and anchors that need management and tying. Our technique provides similar initial fixation strength, has no requirement for extra sutures or anchors, and is very simple to perform.

The supraspinatus tendon is estimated to fail between 800 N and 1000 N.^30,31 Biomechanical shoulder simulators use supraspinatus forces in the range of 20 N to 200 N for scapular plane abduction.^32-36 Therefore, the single-row repair failures in our study fell between functional and full-thickness failure loads. Studies on the mechanics of degenerated human supraspinatus tendon are limited, but there is evidence the mechanical properties of these tissues are inferior to those of healthy tendon.³⁷ A 100-N increase in failure loads with PHA augmentation may prove highly significant in reinforcing the suture–tendon interface in degenerated tendons.

Adding the mesh did not have any effect on gapping at the repair site after cyclic loading. This finding suggests that construct gapping under cyclic loading is not a function of a reinforced knot–tendon interface but is instead caused by microtearing and cinching of the suture constructs in relation to the underlying bone. Tissue elongation likely was not a strong contributor to overall cyclic gapping, as elongation did not differ between the nonaugmented and augmented repairs (0.5 mm vs 0.7 mm; P = .276) and was small relative to the nearly 4 mm of construct gapping. Gapping may be affected by healing and integration of the mesh into the repaired tendon over time, but this effect could not be captured in the present study. Patients are initially immobilized and passive shoulder motion gradually introduced, in stark contrast to the immediate loading protocol in the present study. Regardless, the 25% increase in overall strength may be clinically important, especially in cases of difficult repair or poor tissue quality.

Our technique simplifies arthroscopic augmentation—stitches are passed through the rotator cuff in simple fashion. Before being tied, the limbs that were passed through the rotator cuff are removed through a cannula and then passed through the synthetic graft.

The graft is then shuttled into the subacromial space, and all the suture limbs are tied simply (Figures 5A, 5B). Even though this implementation is simple, our data showed the construct increases overall failure loads by about 25% with no effect on construct elongation.

 

Study Limitations

This study had several limitations. First, it was a cadaveric biomechanical study that evaluated only time-zero biomechanical properties. Loads were normalized to tendon size, specimens were randomized between sides, and paired specimens were used to minimize the effects of tendon and bone quality on outcome metrics. In addition, donor tendons were representative of otherwise healthy tissue. Chronic tears and associated resorption/atrophy could have affected the magnitude of forces and gapping detected in this study. Theoretically, over time the tendon tissue will adhere to and grow into the mesh, which could minimize potential differences. Studies are needed to determine the effects of healing on long-term repair strength in affected patients. Last, all constructs were performed in open fashion to improve repeatability of construct placement and provide accessibility for Instron testing. Our technique did not directly replicate the arthroscopic approach, but, unlike other augmentation techniques, it is so simple that transition to all-arthroscopic augmentation is realistic.

Patch augmentation increases the cost of materials and operative time and should be considered a limitation of its utility. We do not recommend augmentation in all RCRs, as it likely is cost-ineffective. Instead, we recommend augmentation in cases of poor tissue quality, which could lead to healing failure, revision surgery, and higher overall patient costs beyond the cost of adding augmentation. Similarly, we recommend augmentation for revision cases in which tendon healing has failed and tissue quality is poor. The goal is to prevent another failure.

Conclusion

PHA graft augmentation of single-row triple-loaded anchor repairs of the supraspinatus tendon improves the overall ultimate load to failure by 25%. There was no difference in gap formation after cyclic loading between augmented and nonaugmented repairs. This technique for arthroscopic augmentation can be used to improve initial biomechanical repair strength in tears at risk for failure.

Am J Orthop. 2016;45(7):E527-E533. Copyright Frontline Medical Communications Inc. 2016. All rights reserved.

Healing after rotator cuff repair (RCR) can be challenging, especially in cases of large and massive tears, revision repairs, and tendons with poor tissue quality.^1-3 Poor tissue quality is associated with increased risk for recurrent tears, independent of age and tear size.³ Various techniques have been used to improve tendon fixation strength in these difficult situations, including augmented suture configurations (eg, massive cuff stitches, rip-stop stitches) and tissue grafts (eg, acellular dermal matrix).^4-9 Clinical studies have found improved healing rates for larger tears and revision repairs using acellular dermal matrix grafts.^6,10 Synthetic patches are another option for RCR augmentation, but limited clinical data and biomechanical evidence support use of synthetic grafts as an augment for RCRs.^11-13

Polyhydroxyalkanoates (PHAs) are a class of biodegradable polymers that have been used as orthopedic devices, tissue scaffolds, patches, and other applications with increasing frequency over the past decade.¹⁴ In the laboratory, these implanted materials have been shown to support cell migration and growth.¹⁵ The PHA family of polymers typically degrades by hydrolytic and bacterial depolymerase mechanisms over 52-plus weeks in vivo.¹⁴PHA grafts have been studied in the setting of RCR. An expanded polytetrafluoroethylene scaffold was shown to improve repair mechanics when used as a bursal side graft in an in vitro ovine model.¹¹ The graft increased tendon footprint contact pressure and failure loads by almost 180 N. In clinical studies, poly-L-lactic acid augmentations have been used to reinforce massive RCRs. Lenart and colleagues¹⁶ found that 38% of 16 patients with such tears had an intact rotator cuff at 1.2-year follow-up, and improvement in clinical scores. Proctor¹³ reported on use of a poly-L-lactic acid retrograde patch for reinforcement of massive tears with both single- and double-row repairs in 18 patients. The cohort had more favorable rates of intact cuffs at 12 months (83%) and 42 months (78%), and ASES (American Shoulder and Elbow Surgeons) scores improved from 25 before surgery to 82 at latest follow-up after surgery.

RCR augmentation traditionally has been performed with an open or mini-open technique.⁶ Recently, several authors have reported on arthroscopic techniques for augmentation with either acellular dermal matrix or synthetic grafts.^13,17,18 Most techniques have involved “bridging” with a graft or patch used to stress-shield a single-row repair.^8,9,13 This bridging typically involves placing several sutures medial to where the anchor repair stitches pass through the tendon. An alternative is to pass the repair stitches through both the tendon and the graft.^17-19 The overall volume of tissue incorporated into the repair stitches (rotator cuff plus graft) is increased with the augmented technique relative to the bridging technique. Both can be technically challenging, but the augmented technique may be easier to perform arthroscopically.^9,19 Regardless, these techniques are complicated and require a higher level of arthroscopic skills compared with those required in arthroscopic RCR without a graft. Simplifying arthroscopic graft augmentation likely will increase its utility because, even for skilled surgeons, adding a graft can increase operative time by 20 to 30 minutes. Simplification will also extend use of the technique to surgeons with less experience and proficiency with arthroscopic repair.

We developed a simple method for augmenting single-row RCR with a strip of bioresorbable soft-tissue scaffold. We also conducted a study to evaluate the initial biomechanical properties of single-row RCR in cadaveric shoulder specimens augmented with PHA mesh (BioFiber; Tornier) graft as compared with single-row RCR without augmentation. Both cyclic gap formation and ultimate failure loads and displacement were quantified. We hypothesized that the augmented RCRs would have decreased gap formation and increased ultimate failure loads compared with nonaugmented RCRs. This study was exempt from having to obtain Institutional Review Board approval.

Methods

Eight pairs of fresh-frozen cadaver humeri (6 male, 2 female; mean [SD] age, 61 [9] years) were dissected of all soft tissue (except rotator cuff) by Dr. Tashjian, a board-certified, fellowship-trained orthopedic surgeon. There were no qualitative differences in tendon condition between tendons within a pair. The supraspinatus muscle and tendon were separated from the other rotator cuff muscles. The infraspinatus, subscapularis, and teres minor were removed from the humerus. Last, the supraspinatus was resected at its insertion. Humeral pairs were then randomized into augmented and nonaugmented RCRs within each pair.

In the nonaugmented group, the supraspinatus was reattached to its insertion in a single-row RCR with 2 triple-loaded suture anchors (5.5-mm Insite FT Ti, No. 2 Force Fiber suture; Tornier) and 6 simple stitches (Figure 1A). Anchors were placed midway between the articular margin and the lateral edge of the greater tuberosity at about 45° to the bone surface.

Anchors were separated by 15 mm, with the anterior anchor 5 mm posterior to the biceps groove. Stitches were passed through the supraspinatus tendon, taking a 15-mm bite of tissue, with each stitch separated by 5 mm. Each suture was then tied with a Revo knot.

In the contralateral shoulders, augmented RCRs were performed. Specimens were prepared exactly as they were for the nonaugmented RCRs, including anchor placement and suture passage. Before knot tying, RCRs were augmented with 2 strips of 13-mm × 23-mm PHA mesh (BioFiber) (Figure 1B). One strip was used to augment the 3 sutures of each anchor, overlying the residual tendon, to reinforce the tendon–knot interface. After each suture was passed through the supraspinatus tendon from the intra-articular surface, the stitch was passed through the strip of PHA mesh. Stitches were separated by 5 mm in each mesh strip. All 6 sutures were then tied with a Revo knot between the free end of each suture leg and the leg that passed through the tendon and mesh.

Each humerus was transected at the midshaft and potted and mounted in an Instron 1331 load frame with Model 8800 controller (Instron). A cryoclamp was used to grasp the supraspinatus muscle belly above the musculotendinous junction (Figure 2).

The humerus was aligned in the mounting fixture such that loading was performed at a 135° angle with the humeral shaft (Figure 2).²⁰ The Instron, which was equipped with a 1-kN load cell (Dynacell Model 2527-130; Instron) to monitor applied force, measured applied displacement.

Three rows of 2-mm fiducial markers were affixed to the bone, tendon, and muscle belly with cyanoacrylate for tracking with a digital video system (DMAS Version 6.5; Spicatek) (Figure 3).21

Camera resolution was 1360 pixels × 1024 pixels, and DMAS accuracy for marker centroid tracking was rated at ± 0.005 mm. Construct gapping was defined as the difference in displacement between the markers at the tissue–suture interface and the markers on the bone. Tissue deformation was then defined as the displacement between the markers at the tissue–suture interface and the markers on the muscle belly. Mean gapping was defined from anterior to posterior across the construct using 3 sets of fiducial markers.

A 0.1-MPa pre-stress (applied force/tendon cross-sectional area) was applied to each construct to determine the starting position for the deformation profile. Each repair underwent 1000 cycles of uniaxial load-controlled displacement between 0.1 and 1.0 MPa of effective stress at 1 Hz. Effective stress was determined as the ratio of applied force to cross-sectional area of the tendon at harvest to normalize the applied loads between tendons of varying size. During cyclic testing, gapping of more than 5 mm was defined as construct failure.²² After cyclic loading, each construct was loaded to failure at 1.0 mm/s. Ultimate failure load was defined as the highest load achieved at the maximum displacement before rapid decline in load supported by the construct.

 

Statistical Analysis

Paired t tests were used to compare the matched pairs of constructs. For all tests, significance was set at P ≤ .05. Post hoc power was calculated for significant results using G*Power Version 3.1.6.²³ All data are presented as means (SDs).

Results

After 1000 cycles of displacement, mean (SD) gapping was 3.8 (0.9) mm for the nonaugmented repairs and 3.9 (1.1) mm for the PHA mesh–augmented repairs (P = .879) (Figure 4).

Mean (SD) tissue elongation above the construct was comparable (P = .276) between nonaugmented repairs, 0.5 (0.4) mm, and augmented repairs, 0.7 (0.4) mm. No specimens failed during cyclic load, as mean gapping was <4 mm²² in all constructs. Mean (SD) applied force was 11.8 (1.8) N at 0.1 MPa of effective stress and 117.8 (18.1) N at 1.0 MPa of effective stress. Applied force did not vary between constructs (P = .727).

For the nonaugmented repairs, mean (SD) failure displacement was 6.3 (1.7) mm, and mean (SD) ultimate failure load was 472.1 (120.3) N. For the PHA-augmented repairs, failure displacement was 5.5 (1.9) mm, and ultimate failure load was 571.2 (173.0) N. There was no difference in failure displacement (P = .393), but there was a difference in ultimate failure load (P = .042; power = 0.57). During failure testing, mean (SD) tissue deformation was higher (P = .012; power = 0.83) for the PHA-augmented repairs, 1.2 (0.7) mm, than for the nonaugmented repairs, 0.8 (0.5) mm. Failures, which were consistent within pairs, were caused by tissue failure, with sutures pulling through the tissue (4 pairs) or single anchor pullout before ultimate tissue failure (4 pairs). Of the 4 failures with anchor pullout, 3 had anterior anchor pullout, and 1 had posterior anchor pullout. In all specimens with anchor pullout, the second anchor remained stable, and ultimate failure occurred with tissue tearing at the suture interface. There were no significant differences in any metrics between specimens that failed with intact anchors and specimens with single anchor pullout (P ≥ .122). Therefore, both groups were pooled for the failure analysis.

Discussion

RCR augmentation with a synthetic graft is a viable option for improving fixation strength of supraspinatus repairs, as shown in otherwise healthy tendon in the present study. Our hypothesis that there would be decreased gap formation with graft augmentation was not supported, whereas the hypothesis of increased failure loads with graft augmentation was supported. These findings may also be applicable in cases of large tears, revisions, and tendons with poor tissue quality. Simplification of graft application techniques will allow quick and easy arthroscopic augmentation.

Studies of RCRs for large or massive tears have reported retear rates of 25% to 79%.^24-26 Latissimus dorsi tendon transfers also show promise in posterosuperior RCRs, with failure rates near 10%.^27,28 Although use of PHA patches in RCR augmentation is relatively new, short-term and midterm failure rates are in the range of 20% to 60% in the few small cohorts currently being studied.^13,16 It is possible that these rates may improve as indications, surgical experience, and techniques for use of PHA patches are further refined. Regardless, with PHA currently being used in practice, it is important to quantify the biomechanics of the augmentation as a baseline for its performance in reinforcing the tendon–suture interface.

We determined that the initial fixation strength of single-row repairs was higher with the addition of PHA synthetic grafts using a very simple technique. Single-row triple-loaded anchor repairs already provide high initial mechanical strength, and our results are similar to those of another study of this technique.²⁹ Despite the already high mechanical strength of a triple-loaded anchor repair, PHA mesh increased ultimate strength by about 100 N (~25%). Of note, tissue elongation during failure was higher (P = .012; power = 0.83) in the PHA-augmented group (1.2 mm) than in the nonaugmented group (0.8 mm). This was not surprising—failure loads were almost 100 N higher in the PHA-augmented group than in the nonaugmented group. Consequently, much higher forces were placed on the muscle belly, likely resulting in additional elongation of the intact tissue medial to the repair construct.

The ultimate failure loads in our study compare favorably with the biomechanical strength of augmented repairs reported by others.^8,9,18 Barber and colleagues¹⁸ evaluated an augmented single-row repair with 2 double-loaded suture anchors and an acellular dermal matrix graft. The ultimate failure load of the augmented repairs was 325 N. In contrast, Omae and colleagues⁸ tested a bridging single-row repair using 2 double-loaded suture anchors and an acellular dermal matrix graft. Ultimate failure load of the augmented repairs was 560 N, similar to our finding. Last, Shea and colleagues⁹ evaluated a bridging single-row repair using 2 double-loaded suture anchors and an acellular dermal matrix graft, with ultimate failure load of 429 N. The techniques in all 3 studies can be performed arthroscopically but are challenging and require multiple extra sutures and anchors that need management and tying. Our technique provides similar initial fixation strength, has no requirement for extra sutures or anchors, and is very simple to perform.

The supraspinatus tendon is estimated to fail between 800 N and 1000 N.^30,31 Biomechanical shoulder simulators use supraspinatus forces in the range of 20 N to 200 N for scapular plane abduction.^32-36 Therefore, the single-row repair failures in our study fell between functional and full-thickness failure loads. Studies on the mechanics of degenerated human supraspinatus tendon are limited, but there is evidence the mechanical properties of these tissues are inferior to those of healthy tendon.³⁷ A 100-N increase in failure loads with PHA augmentation may prove highly significant in reinforcing the suture–tendon interface in degenerated tendons.

Adding the mesh did not have any effect on gapping at the repair site after cyclic loading. This finding suggests that construct gapping under cyclic loading is not a function of a reinforced knot–tendon interface but is instead caused by microtearing and cinching of the suture constructs in relation to the underlying bone. Tissue elongation likely was not a strong contributor to overall cyclic gapping, as elongation did not differ between the nonaugmented and augmented repairs (0.5 mm vs 0.7 mm; P = .276) and was small relative to the nearly 4 mm of construct gapping. Gapping may be affected by healing and integration of the mesh into the repaired tendon over time, but this effect could not be captured in the present study. Patients are initially immobilized and passive shoulder motion gradually introduced, in stark contrast to the immediate loading protocol in the present study. Regardless, the 25% increase in overall strength may be clinically important, especially in cases of difficult repair or poor tissue quality.

Our technique simplifies arthroscopic augmentation—stitches are passed through the rotator cuff in simple fashion. Before being tied, the limbs that were passed through the rotator cuff are removed through a cannula and then passed through the synthetic graft.

The graft is then shuttled into the subacromial space, and all the suture limbs are tied simply (Figures 5A, 5B). Even though this implementation is simple, our data showed the construct increases overall failure loads by about 25% with no effect on construct elongation.

 

Study Limitations

This study had several limitations. First, it was a cadaveric biomechanical study that evaluated only time-zero biomechanical properties. Loads were normalized to tendon size, specimens were randomized between sides, and paired specimens were used to minimize the effects of tendon and bone quality on outcome metrics. In addition, donor tendons were representative of otherwise healthy tissue. Chronic tears and associated resorption/atrophy could have affected the magnitude of forces and gapping detected in this study. Theoretically, over time the tendon tissue will adhere to and grow into the mesh, which could minimize potential differences. Studies are needed to determine the effects of healing on long-term repair strength in affected patients. Last, all constructs were performed in open fashion to improve repeatability of construct placement and provide accessibility for Instron testing. Our technique did not directly replicate the arthroscopic approach, but, unlike other augmentation techniques, it is so simple that transition to all-arthroscopic augmentation is realistic.

Patch augmentation increases the cost of materials and operative time and should be considered a limitation of its utility. We do not recommend augmentation in all RCRs, as it likely is cost-ineffective. Instead, we recommend augmentation in cases of poor tissue quality, which could lead to healing failure, revision surgery, and higher overall patient costs beyond the cost of adding augmentation. Similarly, we recommend augmentation for revision cases in which tendon healing has failed and tissue quality is poor. The goal is to prevent another failure.

Conclusion

PHA graft augmentation of single-row triple-loaded anchor repairs of the supraspinatus tendon improves the overall ultimate load to failure by 25%. There was no difference in gap formation after cyclic loading between augmented and nonaugmented repairs. This technique for arthroscopic augmentation can be used to improve initial biomechanical repair strength in tears at risk for failure.

Am J Orthop. 2016;45(7):E527-E533. Copyright Frontline Medical Communications Inc. 2016. All rights reserved.

Healing after rotator cuff repair (RCR) can be challenging, especially in cases of large and massive tears, revision repairs, and tendons with poor tissue quality.^1-3 Poor tissue quality is associated with increased risk for recurrent tears, independent of age and tear size.³ Various techniques have been used to improve tendon fixation strength in these difficult situations, including augmented suture configurations (eg, massive cuff stitches, rip-stop stitches) and tissue grafts (eg, acellular dermal matrix).^4-9 Clinical studies have found improved healing rates for larger tears and revision repairs using acellular dermal matrix grafts.^6,10 Synthetic patches are another option for RCR augmentation, but limited clinical data and biomechanical evidence support use of synthetic grafts as an augment for RCRs.^11-13

Polyhydroxyalkanoates (PHAs) are a class of biodegradable polymers that have been used as orthopedic devices, tissue scaffolds, patches, and other applications with increasing frequency over the past decade.¹⁴ In the laboratory, these implanted materials have been shown to support cell migration and growth.¹⁵ The PHA family of polymers typically degrades by hydrolytic and bacterial depolymerase mechanisms over 52-plus weeks in vivo.¹⁴PHA grafts have been studied in the setting of RCR. An expanded polytetrafluoroethylene scaffold was shown to improve repair mechanics when used as a bursal side graft in an in vitro ovine model.¹¹ The graft increased tendon footprint contact pressure and failure loads by almost 180 N. In clinical studies, poly-L-lactic acid augmentations have been used to reinforce massive RCRs. Lenart and colleagues¹⁶ found that 38% of 16 patients with such tears had an intact rotator cuff at 1.2-year follow-up, and improvement in clinical scores. Proctor¹³ reported on use of a poly-L-lactic acid retrograde patch for reinforcement of massive tears with both single- and double-row repairs in 18 patients. The cohort had more favorable rates of intact cuffs at 12 months (83%) and 42 months (78%), and ASES (American Shoulder and Elbow Surgeons) scores improved from 25 before surgery to 82 at latest follow-up after surgery.

RCR augmentation traditionally has been performed with an open or mini-open technique.⁶ Recently, several authors have reported on arthroscopic techniques for augmentation with either acellular dermal matrix or synthetic grafts.^13,17,18 Most techniques have involved “bridging” with a graft or patch used to stress-shield a single-row repair.^8,9,13 This bridging typically involves placing several sutures medial to where the anchor repair stitches pass through the tendon. An alternative is to pass the repair stitches through both the tendon and the graft.^17-19 The overall volume of tissue incorporated into the repair stitches (rotator cuff plus graft) is increased with the augmented technique relative to the bridging technique. Both can be technically challenging, but the augmented technique may be easier to perform arthroscopically.^9,19 Regardless, these techniques are complicated and require a higher level of arthroscopic skills compared with those required in arthroscopic RCR without a graft. Simplifying arthroscopic graft augmentation likely will increase its utility because, even for skilled surgeons, adding a graft can increase operative time by 20 to 30 minutes. Simplification will also extend use of the technique to surgeons with less experience and proficiency with arthroscopic repair.

We developed a simple method for augmenting single-row RCR with a strip of bioresorbable soft-tissue scaffold. We also conducted a study to evaluate the initial biomechanical properties of single-row RCR in cadaveric shoulder specimens augmented with PHA mesh (BioFiber; Tornier) graft as compared with single-row RCR without augmentation. Both cyclic gap formation and ultimate failure loads and displacement were quantified. We hypothesized that the augmented RCRs would have decreased gap formation and increased ultimate failure loads compared with nonaugmented RCRs. This study was exempt from having to obtain Institutional Review Board approval.

Methods

Eight pairs of fresh-frozen cadaver humeri (6 male, 2 female; mean [SD] age, 61 [9] years) were dissected of all soft tissue (except rotator cuff) by Dr. Tashjian, a board-certified, fellowship-trained orthopedic surgeon. There were no qualitative differences in tendon condition between tendons within a pair. The supraspinatus muscle and tendon were separated from the other rotator cuff muscles. The infraspinatus, subscapularis, and teres minor were removed from the humerus. Last, the supraspinatus was resected at its insertion. Humeral pairs were then randomized into augmented and nonaugmented RCRs within each pair.

In the nonaugmented group, the supraspinatus was reattached to its insertion in a single-row RCR with 2 triple-loaded suture anchors (5.5-mm Insite FT Ti, No. 2 Force Fiber suture; Tornier) and 6 simple stitches (Figure 1A). Anchors were placed midway between the articular margin and the lateral edge of the greater tuberosity at about 45° to the bone surface.

Anchors were separated by 15 mm, with the anterior anchor 5 mm posterior to the biceps groove. Stitches were passed through the supraspinatus tendon, taking a 15-mm bite of tissue, with each stitch separated by 5 mm. Each suture was then tied with a Revo knot.

In the contralateral shoulders, augmented RCRs were performed. Specimens were prepared exactly as they were for the nonaugmented RCRs, including anchor placement and suture passage. Before knot tying, RCRs were augmented with 2 strips of 13-mm × 23-mm PHA mesh (BioFiber) (Figure 1B). One strip was used to augment the 3 sutures of each anchor, overlying the residual tendon, to reinforce the tendon–knot interface. After each suture was passed through the supraspinatus tendon from the intra-articular surface, the stitch was passed through the strip of PHA mesh. Stitches were separated by 5 mm in each mesh strip. All 6 sutures were then tied with a Revo knot between the free end of each suture leg and the leg that passed through the tendon and mesh.

Each humerus was transected at the midshaft and potted and mounted in an Instron 1331 load frame with Model 8800 controller (Instron). A cryoclamp was used to grasp the supraspinatus muscle belly above the musculotendinous junction (Figure 2).

The humerus was aligned in the mounting fixture such that loading was performed at a 135° angle with the humeral shaft (Figure 2).²⁰ The Instron, which was equipped with a 1-kN load cell (Dynacell Model 2527-130; Instron) to monitor applied force, measured applied displacement.

Three rows of 2-mm fiducial markers were affixed to the bone, tendon, and muscle belly with cyanoacrylate for tracking with a digital video system (DMAS Version 6.5; Spicatek) (Figure 3).21

Camera resolution was 1360 pixels × 1024 pixels, and DMAS accuracy for marker centroid tracking was rated at ± 0.005 mm. Construct gapping was defined as the difference in displacement between the markers at the tissue–suture interface and the markers on the bone. Tissue deformation was then defined as the displacement between the markers at the tissue–suture interface and the markers on the muscle belly. Mean gapping was defined from anterior to posterior across the construct using 3 sets of fiducial markers.

A 0.1-MPa pre-stress (applied force/tendon cross-sectional area) was applied to each construct to determine the starting position for the deformation profile. Each repair underwent 1000 cycles of uniaxial load-controlled displacement between 0.1 and 1.0 MPa of effective stress at 1 Hz. Effective stress was determined as the ratio of applied force to cross-sectional area of the tendon at harvest to normalize the applied loads between tendons of varying size. During cyclic testing, gapping of more than 5 mm was defined as construct failure.²² After cyclic loading, each construct was loaded to failure at 1.0 mm/s. Ultimate failure load was defined as the highest load achieved at the maximum displacement before rapid decline in load supported by the construct.

 

Statistical Analysis

Paired t tests were used to compare the matched pairs of constructs. For all tests, significance was set at P ≤ .05. Post hoc power was calculated for significant results using G*Power Version 3.1.6.²³ All data are presented as means (SDs).

Results

After 1000 cycles of displacement, mean (SD) gapping was 3.8 (0.9) mm for the nonaugmented repairs and 3.9 (1.1) mm for the PHA mesh–augmented repairs (P = .879) (Figure 4).

Mean (SD) tissue elongation above the construct was comparable (P = .276) between nonaugmented repairs, 0.5 (0.4) mm, and augmented repairs, 0.7 (0.4) mm. No specimens failed during cyclic load, as mean gapping was <4 mm²² in all constructs. Mean (SD) applied force was 11.8 (1.8) N at 0.1 MPa of effective stress and 117.8 (18.1) N at 1.0 MPa of effective stress. Applied force did not vary between constructs (P = .727).

For the nonaugmented repairs, mean (SD) failure displacement was 6.3 (1.7) mm, and mean (SD) ultimate failure load was 472.1 (120.3) N. For the PHA-augmented repairs, failure displacement was 5.5 (1.9) mm, and ultimate failure load was 571.2 (173.0) N. There was no difference in failure displacement (P = .393), but there was a difference in ultimate failure load (P = .042; power = 0.57). During failure testing, mean (SD) tissue deformation was higher (P = .012; power = 0.83) for the PHA-augmented repairs, 1.2 (0.7) mm, than for the nonaugmented repairs, 0.8 (0.5) mm. Failures, which were consistent within pairs, were caused by tissue failure, with sutures pulling through the tissue (4 pairs) or single anchor pullout before ultimate tissue failure (4 pairs). Of the 4 failures with anchor pullout, 3 had anterior anchor pullout, and 1 had posterior anchor pullout. In all specimens with anchor pullout, the second anchor remained stable, and ultimate failure occurred with tissue tearing at the suture interface. There were no significant differences in any metrics between specimens that failed with intact anchors and specimens with single anchor pullout (P ≥ .122). Therefore, both groups were pooled for the failure analysis.

Discussion

RCR augmentation with a synthetic graft is a viable option for improving fixation strength of supraspinatus repairs, as shown in otherwise healthy tendon in the present study. Our hypothesis that there would be decreased gap formation with graft augmentation was not supported, whereas the hypothesis of increased failure loads with graft augmentation was supported. These findings may also be applicable in cases of large tears, revisions, and tendons with poor tissue quality. Simplification of graft application techniques will allow quick and easy arthroscopic augmentation.

Studies of RCRs for large or massive tears have reported retear rates of 25% to 79%.^24-26 Latissimus dorsi tendon transfers also show promise in posterosuperior RCRs, with failure rates near 10%.^27,28 Although use of PHA patches in RCR augmentation is relatively new, short-term and midterm failure rates are in the range of 20% to 60% in the few small cohorts currently being studied.^13,16 It is possible that these rates may improve as indications, surgical experience, and techniques for use of PHA patches are further refined. Regardless, with PHA currently being used in practice, it is important to quantify the biomechanics of the augmentation as a baseline for its performance in reinforcing the tendon–suture interface.

We determined that the initial fixation strength of single-row repairs was higher with the addition of PHA synthetic grafts using a very simple technique. Single-row triple-loaded anchor repairs already provide high initial mechanical strength, and our results are similar to those of another study of this technique.²⁹ Despite the already high mechanical strength of a triple-loaded anchor repair, PHA mesh increased ultimate strength by about 100 N (~25%). Of note, tissue elongation during failure was higher (P = .012; power = 0.83) in the PHA-augmented group (1.2 mm) than in the nonaugmented group (0.8 mm). This was not surprising—failure loads were almost 100 N higher in the PHA-augmented group than in the nonaugmented group. Consequently, much higher forces were placed on the muscle belly, likely resulting in additional elongation of the intact tissue medial to the repair construct.

The ultimate failure loads in our study compare favorably with the biomechanical strength of augmented repairs reported by others.^8,9,18 Barber and colleagues¹⁸ evaluated an augmented single-row repair with 2 double-loaded suture anchors and an acellular dermal matrix graft. The ultimate failure load of the augmented repairs was 325 N. In contrast, Omae and colleagues⁸ tested a bridging single-row repair using 2 double-loaded suture anchors and an acellular dermal matrix graft. Ultimate failure load of the augmented repairs was 560 N, similar to our finding. Last, Shea and colleagues⁹ evaluated a bridging single-row repair using 2 double-loaded suture anchors and an acellular dermal matrix graft, with ultimate failure load of 429 N. The techniques in all 3 studies can be performed arthroscopically but are challenging and require multiple extra sutures and anchors that need management and tying. Our technique provides similar initial fixation strength, has no requirement for extra sutures or anchors, and is very simple to perform.

The supraspinatus tendon is estimated to fail between 800 N and 1000 N.^30,31 Biomechanical shoulder simulators use supraspinatus forces in the range of 20 N to 200 N for scapular plane abduction.^32-36 Therefore, the single-row repair failures in our study fell between functional and full-thickness failure loads. Studies on the mechanics of degenerated human supraspinatus tendon are limited, but there is evidence the mechanical properties of these tissues are inferior to those of healthy tendon.³⁷ A 100-N increase in failure loads with PHA augmentation may prove highly significant in reinforcing the suture–tendon interface in degenerated tendons.

Adding the mesh did not have any effect on gapping at the repair site after cyclic loading. This finding suggests that construct gapping under cyclic loading is not a function of a reinforced knot–tendon interface but is instead caused by microtearing and cinching of the suture constructs in relation to the underlying bone. Tissue elongation likely was not a strong contributor to overall cyclic gapping, as elongation did not differ between the nonaugmented and augmented repairs (0.5 mm vs 0.7 mm; P = .276) and was small relative to the nearly 4 mm of construct gapping. Gapping may be affected by healing and integration of the mesh into the repaired tendon over time, but this effect could not be captured in the present study. Patients are initially immobilized and passive shoulder motion gradually introduced, in stark contrast to the immediate loading protocol in the present study. Regardless, the 25% increase in overall strength may be clinically important, especially in cases of difficult repair or poor tissue quality.

Our technique simplifies arthroscopic augmentation—stitches are passed through the rotator cuff in simple fashion. Before being tied, the limbs that were passed through the rotator cuff are removed through a cannula and then passed through the synthetic graft.

The graft is then shuttled into the subacromial space, and all the suture limbs are tied simply (Figures 5A, 5B). Even though this implementation is simple, our data showed the construct increases overall failure loads by about 25% with no effect on construct elongation.

 

Study Limitations

This study had several limitations. First, it was a cadaveric biomechanical study that evaluated only time-zero biomechanical properties. Loads were normalized to tendon size, specimens were randomized between sides, and paired specimens were used to minimize the effects of tendon and bone quality on outcome metrics. In addition, donor tendons were representative of otherwise healthy tissue. Chronic tears and associated resorption/atrophy could have affected the magnitude of forces and gapping detected in this study. Theoretically, over time the tendon tissue will adhere to and grow into the mesh, which could minimize potential differences. Studies are needed to determine the effects of healing on long-term repair strength in affected patients. Last, all constructs were performed in open fashion to improve repeatability of construct placement and provide accessibility for Instron testing. Our technique did not directly replicate the arthroscopic approach, but, unlike other augmentation techniques, it is so simple that transition to all-arthroscopic augmentation is realistic.

Patch augmentation increases the cost of materials and operative time and should be considered a limitation of its utility. We do not recommend augmentation in all RCRs, as it likely is cost-ineffective. Instead, we recommend augmentation in cases of poor tissue quality, which could lead to healing failure, revision surgery, and higher overall patient costs beyond the cost of adding augmentation. Similarly, we recommend augmentation for revision cases in which tendon healing has failed and tissue quality is poor. The goal is to prevent another failure.

Conclusion

PHA graft augmentation of single-row triple-loaded anchor repairs of the supraspinatus tendon improves the overall ultimate load to failure by 25%. There was no difference in gap formation after cyclic loading between augmented and nonaugmented repairs. This technique for arthroscopic augmentation can be used to improve initial biomechanical repair strength in tears at risk for failure.

Am J Orthop. 2016;45(7):E527-E533. Copyright Frontline Medical Communications Inc. 2016. All rights reserved.

Venous thromboembolism (VTE) after shoulder arthroplasty (SA) is relatively uncommon. Reported rates of VTE development are highly variable, ranging from 0.2% to 13% (pulmonary embolism [PE], 0.2%-10.8%; deep venous thrombosis [DVT], 0.1%-13%).^1-4 Sources of this variability include different methods of capturing cases (small clinical series vs large database studies, which capture mainly hospital readmissions), differences in defining or detecting VTE, and different patient populations (fracture vs osteoarthritis).^1-3 Most studies have also tried to identify factors associated with increased risk for VTE. Risk factors associated with development of VTE after SA include history of VTE, advanced age, prolonged operating room time, higher body mass index (BMI), trauma, history of cancer, female sex, and raised Charlson Comorbidity Index (CCI).^1-7 Limitations of clinical series include the smaller number of reporting institutions—a potential source of bias given regional variability.^1,3,4,7 Limitations of large state or national databases include capturing only events coded during inpatient admission and capturing readmissions for complications at the same institution. This underreporting may lead to very conservative estimates of VTE incidence.^2,5,6,8

In this study, we retrospectively identified all the SAs performed at a single institution over a 13-year period and evaluated the cases for development of VTE (DVT, PE). We hypothesized that the VTE rate would be lower than the very high rates reported by Hoxie and colleagues¹ and Willis and colleagues⁴ but higher than those reported for large state or national databases.^2,3 We also evaluated clotting risk factors, including many never analyzed before.

Materials and Methods

After obtaining Institutional Review Board approval for this study, we searched our database for all SAs performed at our institution between January 1999 and May 2012 and identified cases in which symptomatic VTE developed within the first 90 days after surgery. Charts were reviewed for information on medical history, surgical procedure, and in-hospital and out-of-hospital care within the 90-day postoperative period. We recorded data on symptomatic VTE (DVT, PE) as documented by lower or upper extremity duplex ultrasonography (US) or chest computed tomography (CT) angiography. There had been no routine screening of patients; duplex US or CT angiography was performed only if a patient was clinically symptomatic (leg swelling, leg pain, shortness of breath, tachycardia, chest pain) for a potential DVT or PE. For a patient who had repeat SAs on the same shoulder or bilateral SAs at different times, only the first procedure was included in the analysis. Arthroplasties performed for fracture were excluded.

Study data were collected and managed with REDCap (Research Electronic Data Capture) tools hosted at the University of Utah School of Medicine.⁹ Continuous and discrete data collected on medical history and postoperative course included BMI, age at surgery, preoperative hemoglobin (Hb) and hematocrit (Hct) levels, days in hospital, days until out of bed and days until ambulation (both documented in nursing and physical therapy notes), postoperative Hb and Hct levels, and CCI. Categorical data included sex, diagnosis (primary osteoarthritis, rotator cuff arthropathy, rheumatoid arthritis, failed hemiarthroplasty [HA], failed total SA [TSA], others), attending surgeon, procedure (TSA, HA, reverse TSA, revision SA), anesthesia (general endotracheal anesthesia [GETA] alone, interscalene nerve block alone, GETA plus block), prophylactic use of aspirin after surgery, presence of various medical comorbidities (diabetes, hypertension, cardiac disease, clotting disorders, cancer), hormone replacement therapy, family history of a clotting disorder, and VTE consequences (cardiac events, death).

Statistical Analysis

Descriptive statistics were calculated to summarize aspects of the surgical procedures, the study cohort’s demographics and medical histories, and the incidence of VTE. Logistic regression analysis was performed to explore the association between development of VTE (DVT, PE) and potential risk factors. Unadjusted odds ratios (ORs) were estimated for the risk factors of age, BMI, revision SA, CCI, prophylactic use of aspirin after surgery, preoperative history of VTE, preoperative and postoperative Hb and Hct levels, diabetes, anesthesia (GETA with and without interscalene nerve block), family history of a clotting disorder, days until out of bed, hormone replacement therapy, race, discharge home or to rehabilitation, distance traveled for surgery, hypertension, cardiac disease, cement use, and history of cancer. In addition, ORs were adjusted for age, BMI, and revision SA. For all statistical tests, significance was set at P < .05. All analyses were performed with SAS Version 9.3 (SAS Institute).

Results

We identified 533 SAs: 245 anatomical TSAs, 112 reverse TSAs, 92 HAs, and 84 revision SAs. Three different surgeons performed the procedures, and no patients were lost to follow-up within the first 90 days after surgery. Although SAs were performed for various diagnoses, more than 50% (274) of the SAs were for primary osteoarthritis; 97 were performed for rotator cuff arthropathy, 16 for rheumatoid arthritis, 43 for failed HA, 23 for failed TSA, and 79 for other diagnoses.

 

Of the 533 patients, 288 were female and 245 were male. Mean age at surgery was 65.2 years (range, 16-93 years). Mean (SD) BMI was 29.2 (6.4) kg/m². Mean (SD) preoperative Hb level was 13.7 (1.8) g/dL, and mean preoperative Hct level was 40.1% (4.8%). Mean (SD) length of hospital stay was 2.6 (1.5) days. Mean (SD) time before patients were out of bed was 1.1 (0.7) days. On postoperative day 1, mean Hb level was 11.1 (1.7) g/dL, and mean (SD) Hct level was 33.2% (4.8%). Mean (SD) CCI was 1.1 (0.9).

Anesthesia for the 533 patients consisted of GETA (209 patients, 39.0%), interscalene nerve block (2, 0.4%), or GETA with nerve block (314, 59.0%). After surgery, 125 patients (24.3%) received aspirin as prophylaxis. Diabetes was reported by 83 patients, hypertension by 286, cardiac disease by 74, a history of a clotting disorder by 2, a family history of a clotting disorder by 8, ongoing cancer by 4, a history of cancer by 67, and hormone replacement therapy by 104.

For the entire cohort of 533 patients, the symptomatic VTE rate was 2.6% (14 patients), the DVT rate was 0.9% (5), and the PE rate was 2.3% (12). Although VTE did not cause any deaths, there were 3 cardiac events.

Risk factors significantly associated with increased risk for VTE were raised CCI (OR, 1.858; 95% confidence interval [CI], 1.295–2.665), preoperative thrombotic event (OR, 5.532; 95% CI, 1.651–18.535), lower preoperative Hb level (OR, 0.705; 95% CI, 0.486–1.022), lower preoperative Hct level (OR, 0.877; 95% CI, 0.763–1.007), lower postoperative Hb level (OR, 0.720; 95% CI, 0.506–1.026), diabetes (OR, 5.646; 95% CI, 1.926–16.554), use of GETA without interscalene nerve block (OR, 0.111; 95% CI, 0.014–0.857), higher BMI (OR, 1.148; 95% CI, 1.062–1.241), and revision SA (OR, 5.777; 95% CI, 1.664–20.057).

All factors had significant adjusted ORs, whereas only BMI, revision SA, CCI, diabetes, and use of GETA without nerve block had significant unadjusted ORs (Tables 1, 2).

Discussion

VTE after SA is rare. We report an overall VTE incidence of 2.6%, with DVT at 0.9% and PE at 2.3%. These rates are similar to those reported in clinical series and significantly higher than those reported for large institutional or national databases.^2-7 Our results also support a previously reported trend: The ratio of PE to DVT for SA is significantly higher than historically reported ratios for lower extremity arthroplasty.^2,6-8 We have identified many VTE risk factors: raised CCI, preoperative thrombotic event, lower preoperative Hb and Hct levels, lower postoperative Hb level, diabetes, use of GETA without interscalene nerve block, higher BMI, and revision SA. Results of other studies support 3 findings (higher BMI, raised CCI, preoperative thrombotic event); new findings include correlation with Hb and Hct levels, diabetes, type of anesthesia, and revision SA.^6,7 Identification of these other factors may be useful in making treatment decisions in patients symptomatic after SA and in lowering the threshold for performing diagnostic tests in these patients at risk for VTE.

Reported rates of VTE after SA are highly variable, ranging from 0.2% to 13%.¹⁰ Our rationale for investigating VTE rates at a single institution was to estimate the rates that can be expected in a university-based practice and to determine whether these rates are high enough to warrant routine thromboprophylaxis. The rate variability seems to result in part from variability in the data sources. Most studies that have reported very low VTE rates typically used large state or national databases, which likely were subject to underreporting.

Lyman and colleagues⁶ found 0.5% DVT and 0.2% PE rates in a New York state hospital database, but only in-hospital immediate postoperative symptomatic complications were included; slightly delayed complications may have been missed. Farng and colleagues⁵ reported a 0.6% VTE rate, but only inpatient (immediate postoperative or readmission) events were included; all outpatient events were missed. Jameson and colleagues,² using a national database that included only cases involving inpatient treatment, reported 0% DVT and 0.2% PE rates, again missing outpatient events, and relying on appropriate coding to capture events. Using electronic health records from a large healthcare system, Navarro and colleagues⁸ queried for VTE cases and reported 0.5% DVT and 0.5% PE rates. The inclusiveness of their data source for the outcome of interest was potentially improved relative to national or statewide databases—and the resulting data reported in their study should reflect that improvement. However, the authors relied on ICD–9 (International Classification of Diseases, Ninth Revision) coding to screen for VTE events and excluded patients with prior VTE, preoperative prophylaxis (enoxaparin or warfarin), or follow-up of <90 days. As patients with prior VTE are those most at risk (present study OR, 6-7), excluding them significantly reduces the overall incidence of clotting reported.

Only 4 studies specifically used information drawn directly from physicians’ clinic notes, vs data retrieved (using code-based queries) from databases.^1,3,4,7 These studies may provide a better representation of the rate of VTE after SA, as they were not reliant on codes, included both inpatient and outpatient events, and were inclusive of outpatient follow-up of at least 3 months.

Three of the 4 studies used the Mayo Clinic Total Joint Registry.^1,3,4 Hoxie and colleagues¹ reported an 11% rate of PE after HA performed for fracture (we excluded SA for fracture). As several other investigators have reported an association between trauma and increased risk for VTE, postoperative anticoagulation should be considered in this patient population (though it was not the focus of the present study).^6-8 Sperling and Cofield³ and Singh and colleagues⁷ reported on the risk for PE among SA patients at the Mayo Clinic. Sperling and Cofield³ included only those events that occurred within the first 7 days after surgery; Singh and colleagues⁷ included events out to 90 days after surgery. Sperling and Cofield³ reported a 0.17% PE rate; Singh and colleagues⁷ reported 0.6% PE and 0.1% DVT rates. Sperling and Cofield³ reported on 2885 SAs; Singh and colleagues⁷ reported on 4019 SAs from the same database. As it is unclear whether these 2 studies had complete information on all patients, underreporting may be an issue. Information was obtained through “clinic visits, medical records and/or standardized mailed and telephone-administered questionnaires.”⁷The fourth study, a prospective study of 100 patients by Willis and colleagues,⁴ had the best data on development of symptomatic PE after SA. The authors reported a 2% PE rate and a high (13%) DVT rate. Because US was not performed before the surgical procedures, the number of patients with new and existing DVT cases could not be determined. However, all PEs were new, and the 2% rate found there is similar to the 2.3% in our study. Therefore, we think these rates capture the data most accurately and avoid the underreporting that marks large databases.⁴Studies have identified various factors that increase the risk for VTE after SA. Singh and colleagues⁷ identified the risk factors of age over 70 years, female sex, higher BMI (25-29.9 kg/m²), CCI above 1, traumatic etiology, prior history of VTE, and HA. However, their use of univariate regression analysis may have confounded the effects—one factor may have become a surrogate for another (ie, trauma and HA, as most fractures treated with SA during the study period were treated with HA). Lyman and colleagues⁶ also found advanced age and trauma were associated with higher VTE risk, and reported prior history of cancer as a risk factor as well. Navarro and colleagues⁸ identified trauma as a risk factor, as in the other 2 studies.^6,7 Our data support prior history of VTE, higher BMI, and raised CCI as increasing the risk for VTE.

Other factors identified in the present study are use of GETA without interscalene nerve block, lower preoperative and postoperative Hb levels, diabetes, and revision SA. Because of the limited number of events, only ORs with and without limited control of confounders were performed. Just as in the study by Singh and colleagues,⁷ uncontrolled confounding could have occurred. A nerve block may be protective, as less postoperative pain may allow patients quicker mobilization and therapy. Diabetes may be a surrogate for other medical comorbidities, as reflected by the higher overall risk with raised CCI. Lower preoperative and postoperative Hb levels were associated with clotting and may be representative of patients with poorer overall health and more complicated surgical procedures (eg, revision SA). In an earlier study, we found increased risk for transfusions in revision SA relative to primary SA.¹¹ Lower preoperative Hb level correlated with development of VTE after lower extremity arthroplasty.¹² Postoperative use of aspirin was not found to significantly reduce the incidence of clotting, though this finding may have resulted from lack of power. Therefore, from the present data, there is nothing to conclude about the efficacy of aspirin in preventing thrombosis.

Our findings can be placed in the context of the Virchow triad. Specifically, 3 categories of factors are thought to contribute to thrombosis: hypercoagulability, hemodynamic stasis, and endothelial injury. In grouping factors, we identified prior thrombotic event and obesity as increasing hypercoagulability; revision SA, more comorbidities, lower Hb and Hct levels, diabetes, and GETA as increasing hemodynamic stasis; and revision SA (longer operating room times) as leading to stasis. More comorbidities can be associated with delayed postoperative ambulation, and diabetes and lower Hb and Hct levels can be surrogates for more comorbidities. Surgery performed with the patient under GETA without interscalene nerve block can lead to higher levels of pain and less early mobility.

The present findings have made us more aware of patients at risk for VTE, and we have lowered our threshold for evaluating them for potential clots. Before this study, we used warfarin or enoxaparin for anticoagulation in patients with a history of VTE or active cancer. We are continuing this protocol, but not with other patients. Patients with many comorbidities, lower preoperative Hb level, revision SA, high BMI, or diabetes are carefully monitored for clots early in the postoperative course. Our new threshold for these high-risk patients is to order diagnostic testing, including duplex US or CT angiography. Now, even mild oxygen requirements or mild tachycardia within postoperative week 1 typically prompt a study in these patients. We hope this increased awareness will limit the potential negative consequences associated with development of VTE. Given the present data, we do not think the simple presence of increased comorbidities, lower preoperative Hb, revision SA, high BMI or diabetes should rule out performing SA; rather, it should increase surgeons’ postoperative vigilance in evaluating for potential clots.

Limitations of our study include its retrospective nature and reliance on clinic chart review. Patients were not directly questioned about venous thrombus at follow-up, so all events may not have been captured. Although retrospective review has its drawbacks, it allows for accurate identification of events, even uncoded events. Therefore, more events are likely to be captured with this technique than with large database analyses using only coding information. We tried to identify as many cases as possible by reviewing all outpatient records (orthopedic, nonorthopedic), inpatient records, radiologic studies, and scanned outside records. Another limitation is that having a small number of VTE events limited our ability to perform a multivariate analysis, and uncontrolled confounding likely resulted. Only a very large multi-institutional study can capture enough events to allow a multivariate analysis. A third limitation is that the small number of events may have underpowered the study. Having more patients would have allowed other potential factors to be identified as being significantly associated with VTE. Last, as the study captured only symptomatic VTE events, it may have underreported VTE events. Given our complete review of the medical records, however, most clinically significant events likely were captured.

 

Conclusion

VTE after SA is rare. In our single-institution study, the symptomatic DVT rate was 0.9%, and the symptomatic PE rate was 2.3%. Risk factors associated with clotting included prior VTE, higher BMI, lower preoperative and postoperative Hb levels, raised CCI, diabetes, use of GETA without interscalene nerve block, and revision SA. Risk factors can be used to identify patients who may benefit from a more scrutinized postoperative evaluation and from increased surgeon awareness of the potential for VTE development. Rates of VTE can be used to counsel SA patients regarding overall surgical risks.

Am J Orthop. 2016;45(6):E379-E385. Copyright Frontline Medical Communications Inc. 2016. All rights reserved.

Venous thromboembolism (VTE) after shoulder arthroplasty (SA) is relatively uncommon. Reported rates of VTE development are highly variable, ranging from 0.2% to 13% (pulmonary embolism [PE], 0.2%-10.8%; deep venous thrombosis [DVT], 0.1%-13%).^1-4 Sources of this variability include different methods of capturing cases (small clinical series vs large database studies, which capture mainly hospital readmissions), differences in defining or detecting VTE, and different patient populations (fracture vs osteoarthritis).^1-3 Most studies have also tried to identify factors associated with increased risk for VTE. Risk factors associated with development of VTE after SA include history of VTE, advanced age, prolonged operating room time, higher body mass index (BMI), trauma, history of cancer, female sex, and raised Charlson Comorbidity Index (CCI).^1-7 Limitations of clinical series include the smaller number of reporting institutions—a potential source of bias given regional variability.^1,3,4,7 Limitations of large state or national databases include capturing only events coded during inpatient admission and capturing readmissions for complications at the same institution. This underreporting may lead to very conservative estimates of VTE incidence.^2,5,6,8

In this study, we retrospectively identified all the SAs performed at a single institution over a 13-year period and evaluated the cases for development of VTE (DVT, PE). We hypothesized that the VTE rate would be lower than the very high rates reported by Hoxie and colleagues¹ and Willis and colleagues⁴ but higher than those reported for large state or national databases.^2,3 We also evaluated clotting risk factors, including many never analyzed before.

Materials and Methods

After obtaining Institutional Review Board approval for this study, we searched our database for all SAs performed at our institution between January 1999 and May 2012 and identified cases in which symptomatic VTE developed within the first 90 days after surgery. Charts were reviewed for information on medical history, surgical procedure, and in-hospital and out-of-hospital care within the 90-day postoperative period. We recorded data on symptomatic VTE (DVT, PE) as documented by lower or upper extremity duplex ultrasonography (US) or chest computed tomography (CT) angiography. There had been no routine screening of patients; duplex US or CT angiography was performed only if a patient was clinically symptomatic (leg swelling, leg pain, shortness of breath, tachycardia, chest pain) for a potential DVT or PE. For a patient who had repeat SAs on the same shoulder or bilateral SAs at different times, only the first procedure was included in the analysis. Arthroplasties performed for fracture were excluded.

Study data were collected and managed with REDCap (Research Electronic Data Capture) tools hosted at the University of Utah School of Medicine.⁹ Continuous and discrete data collected on medical history and postoperative course included BMI, age at surgery, preoperative hemoglobin (Hb) and hematocrit (Hct) levels, days in hospital, days until out of bed and days until ambulation (both documented in nursing and physical therapy notes), postoperative Hb and Hct levels, and CCI. Categorical data included sex, diagnosis (primary osteoarthritis, rotator cuff arthropathy, rheumatoid arthritis, failed hemiarthroplasty [HA], failed total SA [TSA], others), attending surgeon, procedure (TSA, HA, reverse TSA, revision SA), anesthesia (general endotracheal anesthesia [GETA] alone, interscalene nerve block alone, GETA plus block), prophylactic use of aspirin after surgery, presence of various medical comorbidities (diabetes, hypertension, cardiac disease, clotting disorders, cancer), hormone replacement therapy, family history of a clotting disorder, and VTE consequences (cardiac events, death).

Statistical Analysis

Descriptive statistics were calculated to summarize aspects of the surgical procedures, the study cohort’s demographics and medical histories, and the incidence of VTE. Logistic regression analysis was performed to explore the association between development of VTE (DVT, PE) and potential risk factors. Unadjusted odds ratios (ORs) were estimated for the risk factors of age, BMI, revision SA, CCI, prophylactic use of aspirin after surgery, preoperative history of VTE, preoperative and postoperative Hb and Hct levels, diabetes, anesthesia (GETA with and without interscalene nerve block), family history of a clotting disorder, days until out of bed, hormone replacement therapy, race, discharge home or to rehabilitation, distance traveled for surgery, hypertension, cardiac disease, cement use, and history of cancer. In addition, ORs were adjusted for age, BMI, and revision SA. For all statistical tests, significance was set at P < .05. All analyses were performed with SAS Version 9.3 (SAS Institute).

Results

We identified 533 SAs: 245 anatomical TSAs, 112 reverse TSAs, 92 HAs, and 84 revision SAs. Three different surgeons performed the procedures, and no patients were lost to follow-up within the first 90 days after surgery. Although SAs were performed for various diagnoses, more than 50% (274) of the SAs were for primary osteoarthritis; 97 were performed for rotator cuff arthropathy, 16 for rheumatoid arthritis, 43 for failed HA, 23 for failed TSA, and 79 for other diagnoses.

 

Of the 533 patients, 288 were female and 245 were male. Mean age at surgery was 65.2 years (range, 16-93 years). Mean (SD) BMI was 29.2 (6.4) kg/m². Mean (SD) preoperative Hb level was 13.7 (1.8) g/dL, and mean preoperative Hct level was 40.1% (4.8%). Mean (SD) length of hospital stay was 2.6 (1.5) days. Mean (SD) time before patients were out of bed was 1.1 (0.7) days. On postoperative day 1, mean Hb level was 11.1 (1.7) g/dL, and mean (SD) Hct level was 33.2% (4.8%). Mean (SD) CCI was 1.1 (0.9).

Anesthesia for the 533 patients consisted of GETA (209 patients, 39.0%), interscalene nerve block (2, 0.4%), or GETA with nerve block (314, 59.0%). After surgery, 125 patients (24.3%) received aspirin as prophylaxis. Diabetes was reported by 83 patients, hypertension by 286, cardiac disease by 74, a history of a clotting disorder by 2, a family history of a clotting disorder by 8, ongoing cancer by 4, a history of cancer by 67, and hormone replacement therapy by 104.

For the entire cohort of 533 patients, the symptomatic VTE rate was 2.6% (14 patients), the DVT rate was 0.9% (5), and the PE rate was 2.3% (12). Although VTE did not cause any deaths, there were 3 cardiac events.

Risk factors significantly associated with increased risk for VTE were raised CCI (OR, 1.858; 95% confidence interval [CI], 1.295–2.665), preoperative thrombotic event (OR, 5.532; 95% CI, 1.651–18.535), lower preoperative Hb level (OR, 0.705; 95% CI, 0.486–1.022), lower preoperative Hct level (OR, 0.877; 95% CI, 0.763–1.007), lower postoperative Hb level (OR, 0.720; 95% CI, 0.506–1.026), diabetes (OR, 5.646; 95% CI, 1.926–16.554), use of GETA without interscalene nerve block (OR, 0.111; 95% CI, 0.014–0.857), higher BMI (OR, 1.148; 95% CI, 1.062–1.241), and revision SA (OR, 5.777; 95% CI, 1.664–20.057).

All factors had significant adjusted ORs, whereas only BMI, revision SA, CCI, diabetes, and use of GETA without nerve block had significant unadjusted ORs (Tables 1, 2).

Discussion

VTE after SA is rare. We report an overall VTE incidence of 2.6%, with DVT at 0.9% and PE at 2.3%. These rates are similar to those reported in clinical series and significantly higher than those reported for large institutional or national databases.^2-7 Our results also support a previously reported trend: The ratio of PE to DVT for SA is significantly higher than historically reported ratios for lower extremity arthroplasty.^2,6-8 We have identified many VTE risk factors: raised CCI, preoperative thrombotic event, lower preoperative Hb and Hct levels, lower postoperative Hb level, diabetes, use of GETA without interscalene nerve block, higher BMI, and revision SA. Results of other studies support 3 findings (higher BMI, raised CCI, preoperative thrombotic event); new findings include correlation with Hb and Hct levels, diabetes, type of anesthesia, and revision SA.^6,7 Identification of these other factors may be useful in making treatment decisions in patients symptomatic after SA and in lowering the threshold for performing diagnostic tests in these patients at risk for VTE.

Reported rates of VTE after SA are highly variable, ranging from 0.2% to 13%.¹⁰ Our rationale for investigating VTE rates at a single institution was to estimate the rates that can be expected in a university-based practice and to determine whether these rates are high enough to warrant routine thromboprophylaxis. The rate variability seems to result in part from variability in the data sources. Most studies that have reported very low VTE rates typically used large state or national databases, which likely were subject to underreporting.

Lyman and colleagues⁶ found 0.5% DVT and 0.2% PE rates in a New York state hospital database, but only in-hospital immediate postoperative symptomatic complications were included; slightly delayed complications may have been missed. Farng and colleagues⁵ reported a 0.6% VTE rate, but only inpatient (immediate postoperative or readmission) events were included; all outpatient events were missed. Jameson and colleagues,² using a national database that included only cases involving inpatient treatment, reported 0% DVT and 0.2% PE rates, again missing outpatient events, and relying on appropriate coding to capture events. Using electronic health records from a large healthcare system, Navarro and colleagues⁸ queried for VTE cases and reported 0.5% DVT and 0.5% PE rates. The inclusiveness of their data source for the outcome of interest was potentially improved relative to national or statewide databases—and the resulting data reported in their study should reflect that improvement. However, the authors relied on ICD–9 (International Classification of Diseases, Ninth Revision) coding to screen for VTE events and excluded patients with prior VTE, preoperative prophylaxis (enoxaparin or warfarin), or follow-up of <90 days. As patients with prior VTE are those most at risk (present study OR, 6-7), excluding them significantly reduces the overall incidence of clotting reported.

Only 4 studies specifically used information drawn directly from physicians’ clinic notes, vs data retrieved (using code-based queries) from databases.^1,3,4,7 These studies may provide a better representation of the rate of VTE after SA, as they were not reliant on codes, included both inpatient and outpatient events, and were inclusive of outpatient follow-up of at least 3 months.

Three of the 4 studies used the Mayo Clinic Total Joint Registry.^1,3,4 Hoxie and colleagues¹ reported an 11% rate of PE after HA performed for fracture (we excluded SA for fracture). As several other investigators have reported an association between trauma and increased risk for VTE, postoperative anticoagulation should be considered in this patient population (though it was not the focus of the present study).^6-8 Sperling and Cofield³ and Singh and colleagues⁷ reported on the risk for PE among SA patients at the Mayo Clinic. Sperling and Cofield³ included only those events that occurred within the first 7 days after surgery; Singh and colleagues⁷ included events out to 90 days after surgery. Sperling and Cofield³ reported a 0.17% PE rate; Singh and colleagues⁷ reported 0.6% PE and 0.1% DVT rates. Sperling and Cofield³ reported on 2885 SAs; Singh and colleagues⁷ reported on 4019 SAs from the same database. As it is unclear whether these 2 studies had complete information on all patients, underreporting may be an issue. Information was obtained through “clinic visits, medical records and/or standardized mailed and telephone-administered questionnaires.”⁷The fourth study, a prospective study of 100 patients by Willis and colleagues,⁴ had the best data on development of symptomatic PE after SA. The authors reported a 2% PE rate and a high (13%) DVT rate. Because US was not performed before the surgical procedures, the number of patients with new and existing DVT cases could not be determined. However, all PEs were new, and the 2% rate found there is similar to the 2.3% in our study. Therefore, we think these rates capture the data most accurately and avoid the underreporting that marks large databases.⁴Studies have identified various factors that increase the risk for VTE after SA. Singh and colleagues⁷ identified the risk factors of age over 70 years, female sex, higher BMI (25-29.9 kg/m²), CCI above 1, traumatic etiology, prior history of VTE, and HA. However, their use of univariate regression analysis may have confounded the effects—one factor may have become a surrogate for another (ie, trauma and HA, as most fractures treated with SA during the study period were treated with HA). Lyman and colleagues⁶ also found advanced age and trauma were associated with higher VTE risk, and reported prior history of cancer as a risk factor as well. Navarro and colleagues⁸ identified trauma as a risk factor, as in the other 2 studies.^6,7 Our data support prior history of VTE, higher BMI, and raised CCI as increasing the risk for VTE.

Other factors identified in the present study are use of GETA without interscalene nerve block, lower preoperative and postoperative Hb levels, diabetes, and revision SA. Because of the limited number of events, only ORs with and without limited control of confounders were performed. Just as in the study by Singh and colleagues,⁷ uncontrolled confounding could have occurred. A nerve block may be protective, as less postoperative pain may allow patients quicker mobilization and therapy. Diabetes may be a surrogate for other medical comorbidities, as reflected by the higher overall risk with raised CCI. Lower preoperative and postoperative Hb levels were associated with clotting and may be representative of patients with poorer overall health and more complicated surgical procedures (eg, revision SA). In an earlier study, we found increased risk for transfusions in revision SA relative to primary SA.¹¹ Lower preoperative Hb level correlated with development of VTE after lower extremity arthroplasty.¹² Postoperative use of aspirin was not found to significantly reduce the incidence of clotting, though this finding may have resulted from lack of power. Therefore, from the present data, there is nothing to conclude about the efficacy of aspirin in preventing thrombosis.

Our findings can be placed in the context of the Virchow triad. Specifically, 3 categories of factors are thought to contribute to thrombosis: hypercoagulability, hemodynamic stasis, and endothelial injury. In grouping factors, we identified prior thrombotic event and obesity as increasing hypercoagulability; revision SA, more comorbidities, lower Hb and Hct levels, diabetes, and GETA as increasing hemodynamic stasis; and revision SA (longer operating room times) as leading to stasis. More comorbidities can be associated with delayed postoperative ambulation, and diabetes and lower Hb and Hct levels can be surrogates for more comorbidities. Surgery performed with the patient under GETA without interscalene nerve block can lead to higher levels of pain and less early mobility.

The present findings have made us more aware of patients at risk for VTE, and we have lowered our threshold for evaluating them for potential clots. Before this study, we used warfarin or enoxaparin for anticoagulation in patients with a history of VTE or active cancer. We are continuing this protocol, but not with other patients. Patients with many comorbidities, lower preoperative Hb level, revision SA, high BMI, or diabetes are carefully monitored for clots early in the postoperative course. Our new threshold for these high-risk patients is to order diagnostic testing, including duplex US or CT angiography. Now, even mild oxygen requirements or mild tachycardia within postoperative week 1 typically prompt a study in these patients. We hope this increased awareness will limit the potential negative consequences associated with development of VTE. Given the present data, we do not think the simple presence of increased comorbidities, lower preoperative Hb, revision SA, high BMI or diabetes should rule out performing SA; rather, it should increase surgeons’ postoperative vigilance in evaluating for potential clots.

Limitations of our study include its retrospective nature and reliance on clinic chart review. Patients were not directly questioned about venous thrombus at follow-up, so all events may not have been captured. Although retrospective review has its drawbacks, it allows for accurate identification of events, even uncoded events. Therefore, more events are likely to be captured with this technique than with large database analyses using only coding information. We tried to identify as many cases as possible by reviewing all outpatient records (orthopedic, nonorthopedic), inpatient records, radiologic studies, and scanned outside records. Another limitation is that having a small number of VTE events limited our ability to perform a multivariate analysis, and uncontrolled confounding likely resulted. Only a very large multi-institutional study can capture enough events to allow a multivariate analysis. A third limitation is that the small number of events may have underpowered the study. Having more patients would have allowed other potential factors to be identified as being significantly associated with VTE. Last, as the study captured only symptomatic VTE events, it may have underreported VTE events. Given our complete review of the medical records, however, most clinically significant events likely were captured.

 

Conclusion

VTE after SA is rare. In our single-institution study, the symptomatic DVT rate was 0.9%, and the symptomatic PE rate was 2.3%. Risk factors associated with clotting included prior VTE, higher BMI, lower preoperative and postoperative Hb levels, raised CCI, diabetes, use of GETA without interscalene nerve block, and revision SA. Risk factors can be used to identify patients who may benefit from a more scrutinized postoperative evaluation and from increased surgeon awareness of the potential for VTE development. Rates of VTE can be used to counsel SA patients regarding overall surgical risks.

Am J Orthop. 2016;45(6):E379-E385. Copyright Frontline Medical Communications Inc. 2016. All rights reserved.

Venous thromboembolism (VTE) after shoulder arthroplasty (SA) is relatively uncommon. Reported rates of VTE development are highly variable, ranging from 0.2% to 13% (pulmonary embolism [PE], 0.2%-10.8%; deep venous thrombosis [DVT], 0.1%-13%).^1-4 Sources of this variability include different methods of capturing cases (small clinical series vs large database studies, which capture mainly hospital readmissions), differences in defining or detecting VTE, and different patient populations (fracture vs osteoarthritis).^1-3 Most studies have also tried to identify factors associated with increased risk for VTE. Risk factors associated with development of VTE after SA include history of VTE, advanced age, prolonged operating room time, higher body mass index (BMI), trauma, history of cancer, female sex, and raised Charlson Comorbidity Index (CCI).^1-7 Limitations of clinical series include the smaller number of reporting institutions—a potential source of bias given regional variability.^1,3,4,7 Limitations of large state or national databases include capturing only events coded during inpatient admission and capturing readmissions for complications at the same institution. This underreporting may lead to very conservative estimates of VTE incidence.^2,5,6,8

In this study, we retrospectively identified all the SAs performed at a single institution over a 13-year period and evaluated the cases for development of VTE (DVT, PE). We hypothesized that the VTE rate would be lower than the very high rates reported by Hoxie and colleagues¹ and Willis and colleagues⁴ but higher than those reported for large state or national databases.^2,3 We also evaluated clotting risk factors, including many never analyzed before.

Materials and Methods

After obtaining Institutional Review Board approval for this study, we searched our database for all SAs performed at our institution between January 1999 and May 2012 and identified cases in which symptomatic VTE developed within the first 90 days after surgery. Charts were reviewed for information on medical history, surgical procedure, and in-hospital and out-of-hospital care within the 90-day postoperative period. We recorded data on symptomatic VTE (DVT, PE) as documented by lower or upper extremity duplex ultrasonography (US) or chest computed tomography (CT) angiography. There had been no routine screening of patients; duplex US or CT angiography was performed only if a patient was clinically symptomatic (leg swelling, leg pain, shortness of breath, tachycardia, chest pain) for a potential DVT or PE. For a patient who had repeat SAs on the same shoulder or bilateral SAs at different times, only the first procedure was included in the analysis. Arthroplasties performed for fracture were excluded.

Study data were collected and managed with REDCap (Research Electronic Data Capture) tools hosted at the University of Utah School of Medicine.⁹ Continuous and discrete data collected on medical history and postoperative course included BMI, age at surgery, preoperative hemoglobin (Hb) and hematocrit (Hct) levels, days in hospital, days until out of bed and days until ambulation (both documented in nursing and physical therapy notes), postoperative Hb and Hct levels, and CCI. Categorical data included sex, diagnosis (primary osteoarthritis, rotator cuff arthropathy, rheumatoid arthritis, failed hemiarthroplasty [HA], failed total SA [TSA], others), attending surgeon, procedure (TSA, HA, reverse TSA, revision SA), anesthesia (general endotracheal anesthesia [GETA] alone, interscalene nerve block alone, GETA plus block), prophylactic use of aspirin after surgery, presence of various medical comorbidities (diabetes, hypertension, cardiac disease, clotting disorders, cancer), hormone replacement therapy, family history of a clotting disorder, and VTE consequences (cardiac events, death).

Statistical Analysis

Descriptive statistics were calculated to summarize aspects of the surgical procedures, the study cohort’s demographics and medical histories, and the incidence of VTE. Logistic regression analysis was performed to explore the association between development of VTE (DVT, PE) and potential risk factors. Unadjusted odds ratios (ORs) were estimated for the risk factors of age, BMI, revision SA, CCI, prophylactic use of aspirin after surgery, preoperative history of VTE, preoperative and postoperative Hb and Hct levels, diabetes, anesthesia (GETA with and without interscalene nerve block), family history of a clotting disorder, days until out of bed, hormone replacement therapy, race, discharge home or to rehabilitation, distance traveled for surgery, hypertension, cardiac disease, cement use, and history of cancer. In addition, ORs were adjusted for age, BMI, and revision SA. For all statistical tests, significance was set at P < .05. All analyses were performed with SAS Version 9.3 (SAS Institute).

Results

We identified 533 SAs: 245 anatomical TSAs, 112 reverse TSAs, 92 HAs, and 84 revision SAs. Three different surgeons performed the procedures, and no patients were lost to follow-up within the first 90 days after surgery. Although SAs were performed for various diagnoses, more than 50% (274) of the SAs were for primary osteoarthritis; 97 were performed for rotator cuff arthropathy, 16 for rheumatoid arthritis, 43 for failed HA, 23 for failed TSA, and 79 for other diagnoses.

 

Of the 533 patients, 288 were female and 245 were male. Mean age at surgery was 65.2 years (range, 16-93 years). Mean (SD) BMI was 29.2 (6.4) kg/m². Mean (SD) preoperative Hb level was 13.7 (1.8) g/dL, and mean preoperative Hct level was 40.1% (4.8%). Mean (SD) length of hospital stay was 2.6 (1.5) days. Mean (SD) time before patients were out of bed was 1.1 (0.7) days. On postoperative day 1, mean Hb level was 11.1 (1.7) g/dL, and mean (SD) Hct level was 33.2% (4.8%). Mean (SD) CCI was 1.1 (0.9).

Anesthesia for the 533 patients consisted of GETA (209 patients, 39.0%), interscalene nerve block (2, 0.4%), or GETA with nerve block (314, 59.0%). After surgery, 125 patients (24.3%) received aspirin as prophylaxis. Diabetes was reported by 83 patients, hypertension by 286, cardiac disease by 74, a history of a clotting disorder by 2, a family history of a clotting disorder by 8, ongoing cancer by 4, a history of cancer by 67, and hormone replacement therapy by 104.

For the entire cohort of 533 patients, the symptomatic VTE rate was 2.6% (14 patients), the DVT rate was 0.9% (5), and the PE rate was 2.3% (12). Although VTE did not cause any deaths, there were 3 cardiac events.

Risk factors significantly associated with increased risk for VTE were raised CCI (OR, 1.858; 95% confidence interval [CI], 1.295–2.665), preoperative thrombotic event (OR, 5.532; 95% CI, 1.651–18.535), lower preoperative Hb level (OR, 0.705; 95% CI, 0.486–1.022), lower preoperative Hct level (OR, 0.877; 95% CI, 0.763–1.007), lower postoperative Hb level (OR, 0.720; 95% CI, 0.506–1.026), diabetes (OR, 5.646; 95% CI, 1.926–16.554), use of GETA without interscalene nerve block (OR, 0.111; 95% CI, 0.014–0.857), higher BMI (OR, 1.148; 95% CI, 1.062–1.241), and revision SA (OR, 5.777; 95% CI, 1.664–20.057).

All factors had significant adjusted ORs, whereas only BMI, revision SA, CCI, diabetes, and use of GETA without nerve block had significant unadjusted ORs (Tables 1, 2).

Discussion

VTE after SA is rare. We report an overall VTE incidence of 2.6%, with DVT at 0.9% and PE at 2.3%. These rates are similar to those reported in clinical series and significantly higher than those reported for large institutional or national databases.^2-7 Our results also support a previously reported trend: The ratio of PE to DVT for SA is significantly higher than historically reported ratios for lower extremity arthroplasty.^2,6-8 We have identified many VTE risk factors: raised CCI, preoperative thrombotic event, lower preoperative Hb and Hct levels, lower postoperative Hb level, diabetes, use of GETA without interscalene nerve block, higher BMI, and revision SA. Results of other studies support 3 findings (higher BMI, raised CCI, preoperative thrombotic event); new findings include correlation with Hb and Hct levels, diabetes, type of anesthesia, and revision SA.^6,7 Identification of these other factors may be useful in making treatment decisions in patients symptomatic after SA and in lowering the threshold for performing diagnostic tests in these patients at risk for VTE.

Reported rates of VTE after SA are highly variable, ranging from 0.2% to 13%.¹⁰ Our rationale for investigating VTE rates at a single institution was to estimate the rates that can be expected in a university-based practice and to determine whether these rates are high enough to warrant routine thromboprophylaxis. The rate variability seems to result in part from variability in the data sources. Most studies that have reported very low VTE rates typically used large state or national databases, which likely were subject to underreporting.

Lyman and colleagues⁶ found 0.5% DVT and 0.2% PE rates in a New York state hospital database, but only in-hospital immediate postoperative symptomatic complications were included; slightly delayed complications may have been missed. Farng and colleagues⁵ reported a 0.6% VTE rate, but only inpatient (immediate postoperative or readmission) events were included; all outpatient events were missed. Jameson and colleagues,² using a national database that included only cases involving inpatient treatment, reported 0% DVT and 0.2% PE rates, again missing outpatient events, and relying on appropriate coding to capture events. Using electronic health records from a large healthcare system, Navarro and colleagues⁸ queried for VTE cases and reported 0.5% DVT and 0.5% PE rates. The inclusiveness of their data source for the outcome of interest was potentially improved relative to national or statewide databases—and the resulting data reported in their study should reflect that improvement. However, the authors relied on ICD–9 (International Classification of Diseases, Ninth Revision) coding to screen for VTE events and excluded patients with prior VTE, preoperative prophylaxis (enoxaparin or warfarin), or follow-up of <90 days. As patients with prior VTE are those most at risk (present study OR, 6-7), excluding them significantly reduces the overall incidence of clotting reported.

Only 4 studies specifically used information drawn directly from physicians’ clinic notes, vs data retrieved (using code-based queries) from databases.^1,3,4,7 These studies may provide a better representation of the rate of VTE after SA, as they were not reliant on codes, included both inpatient and outpatient events, and were inclusive of outpatient follow-up of at least 3 months.

Three of the 4 studies used the Mayo Clinic Total Joint Registry.^1,3,4 Hoxie and colleagues¹ reported an 11% rate of PE after HA performed for fracture (we excluded SA for fracture). As several other investigators have reported an association between trauma and increased risk for VTE, postoperative anticoagulation should be considered in this patient population (though it was not the focus of the present study).^6-8 Sperling and Cofield³ and Singh and colleagues⁷ reported on the risk for PE among SA patients at the Mayo Clinic. Sperling and Cofield³ included only those events that occurred within the first 7 days after surgery; Singh and colleagues⁷ included events out to 90 days after surgery. Sperling and Cofield³ reported a 0.17% PE rate; Singh and colleagues⁷ reported 0.6% PE and 0.1% DVT rates. Sperling and Cofield³ reported on 2885 SAs; Singh and colleagues⁷ reported on 4019 SAs from the same database. As it is unclear whether these 2 studies had complete information on all patients, underreporting may be an issue. Information was obtained through “clinic visits, medical records and/or standardized mailed and telephone-administered questionnaires.”⁷The fourth study, a prospective study of 100 patients by Willis and colleagues,⁴ had the best data on development of symptomatic PE after SA. The authors reported a 2% PE rate and a high (13%) DVT rate. Because US was not performed before the surgical procedures, the number of patients with new and existing DVT cases could not be determined. However, all PEs were new, and the 2% rate found there is similar to the 2.3% in our study. Therefore, we think these rates capture the data most accurately and avoid the underreporting that marks large databases.⁴Studies have identified various factors that increase the risk for VTE after SA. Singh and colleagues⁷ identified the risk factors of age over 70 years, female sex, higher BMI (25-29.9 kg/m²), CCI above 1, traumatic etiology, prior history of VTE, and HA. However, their use of univariate regression analysis may have confounded the effects—one factor may have become a surrogate for another (ie, trauma and HA, as most fractures treated with SA during the study period were treated with HA). Lyman and colleagues⁶ also found advanced age and trauma were associated with higher VTE risk, and reported prior history of cancer as a risk factor as well. Navarro and colleagues⁸ identified trauma as a risk factor, as in the other 2 studies.^6,7 Our data support prior history of VTE, higher BMI, and raised CCI as increasing the risk for VTE.

Other factors identified in the present study are use of GETA without interscalene nerve block, lower preoperative and postoperative Hb levels, diabetes, and revision SA. Because of the limited number of events, only ORs with and without limited control of confounders were performed. Just as in the study by Singh and colleagues,⁷ uncontrolled confounding could have occurred. A nerve block may be protective, as less postoperative pain may allow patients quicker mobilization and therapy. Diabetes may be a surrogate for other medical comorbidities, as reflected by the higher overall risk with raised CCI. Lower preoperative and postoperative Hb levels were associated with clotting and may be representative of patients with poorer overall health and more complicated surgical procedures (eg, revision SA). In an earlier study, we found increased risk for transfusions in revision SA relative to primary SA.¹¹ Lower preoperative Hb level correlated with development of VTE after lower extremity arthroplasty.¹² Postoperative use of aspirin was not found to significantly reduce the incidence of clotting, though this finding may have resulted from lack of power. Therefore, from the present data, there is nothing to conclude about the efficacy of aspirin in preventing thrombosis.

Our findings can be placed in the context of the Virchow triad. Specifically, 3 categories of factors are thought to contribute to thrombosis: hypercoagulability, hemodynamic stasis, and endothelial injury. In grouping factors, we identified prior thrombotic event and obesity as increasing hypercoagulability; revision SA, more comorbidities, lower Hb and Hct levels, diabetes, and GETA as increasing hemodynamic stasis; and revision SA (longer operating room times) as leading to stasis. More comorbidities can be associated with delayed postoperative ambulation, and diabetes and lower Hb and Hct levels can be surrogates for more comorbidities. Surgery performed with the patient under GETA without interscalene nerve block can lead to higher levels of pain and less early mobility.

The present findings have made us more aware of patients at risk for VTE, and we have lowered our threshold for evaluating them for potential clots. Before this study, we used warfarin or enoxaparin for anticoagulation in patients with a history of VTE or active cancer. We are continuing this protocol, but not with other patients. Patients with many comorbidities, lower preoperative Hb level, revision SA, high BMI, or diabetes are carefully monitored for clots early in the postoperative course. Our new threshold for these high-risk patients is to order diagnostic testing, including duplex US or CT angiography. Now, even mild oxygen requirements or mild tachycardia within postoperative week 1 typically prompt a study in these patients. We hope this increased awareness will limit the potential negative consequences associated with development of VTE. Given the present data, we do not think the simple presence of increased comorbidities, lower preoperative Hb, revision SA, high BMI or diabetes should rule out performing SA; rather, it should increase surgeons’ postoperative vigilance in evaluating for potential clots.

Limitations of our study include its retrospective nature and reliance on clinic chart review. Patients were not directly questioned about venous thrombus at follow-up, so all events may not have been captured. Although retrospective review has its drawbacks, it allows for accurate identification of events, even uncoded events. Therefore, more events are likely to be captured with this technique than with large database analyses using only coding information. We tried to identify as many cases as possible by reviewing all outpatient records (orthopedic, nonorthopedic), inpatient records, radiologic studies, and scanned outside records. Another limitation is that having a small number of VTE events limited our ability to perform a multivariate analysis, and uncontrolled confounding likely resulted. Only a very large multi-institutional study can capture enough events to allow a multivariate analysis. A third limitation is that the small number of events may have underpowered the study. Having more patients would have allowed other potential factors to be identified as being significantly associated with VTE. Last, as the study captured only symptomatic VTE events, it may have underreported VTE events. Given our complete review of the medical records, however, most clinically significant events likely were captured.

 

Conclusion

VTE after SA is rare. In our single-institution study, the symptomatic DVT rate was 0.9%, and the symptomatic PE rate was 2.3%. Risk factors associated with clotting included prior VTE, higher BMI, lower preoperative and postoperative Hb levels, raised CCI, diabetes, use of GETA without interscalene nerve block, and revision SA. Risk factors can be used to identify patients who may benefit from a more scrutinized postoperative evaluation and from increased surgeon awareness of the potential for VTE development. Rates of VTE can be used to counsel SA patients regarding overall surgical risks.

Am J Orthop. 2016;45(6):E379-E385. Copyright Frontline Medical Communications Inc. 2016. All rights reserved.